Novartis's Zolgensma Finds Commercial Legs In A First For Gene Therapy

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Zolgensma generated $160m in the third quarter, a strong launch for the gene therapy's first full quarter on the market.

Paper plane as spaceship flying above clouds to another planet, mars. Business background for success, launch, startup, technology innovation, exploration, mission. Eps10 vector illustration. - Vector
Novartis' Zolgensma got off to a strong start

Novartis AG's gene therapy Zolgensma generated $160m in the third quarter, its first full quarter on the market, a strong launch for any new drug in today's challenging launch environment. Zolgensma (onasemnogene abeparvovec) is not the first gene therapy to reach the market in the US or Europe, but it looks like it will be the first to attain commercial traction.

Sales of Zolgensma outpaced analyst expectations, which generally predicted sales in a range around $100m for the gene therapy for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.